A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

614

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: Teclistamab
DRUG: Pomalidomide
DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Carfilzomib

Sponsor

Janssen Research & Development, LLC